Lens enables you to analyze Tempus’ library of 6M+ de-identified research records, helping to uncover critical insights that can accelerate innovation and improve patient outcomes.
Enhance data-driven R&D strategy
Read press releaseTempus provides integrated solutions to help meet your needs from early discovery through commercialization.
Lens enables you to analyze Tempus’ library of 6M+ de-identified research records, helping to uncover critical insights that can accelerate innovation and improve patient outcomes.
Use our genomic platform to prospectively sequence through clinical trials and retrospectively support research priorities.
Leverage real-world datasets of matched molecular and clinical data with digital whole slide pathology images to uncover new insights across the research and development spectrum.
Leverage our robust biobank of patient-derived tumor organoids to accelerate drug discovery.
Integrate CDx claims into Tempus assays through a validated and established sequencing platform to pursue companion diagnostic biomarkers.
Discover unique molecular targets, track methylation patterns, and build multimodal datasets with our robust suite of high throughput multi-omic solutions.
Bring discoveries from the lab to market through our full-service CRO.
Utilize NGS and EMR integrations to identify patients that match your study's eligibility criteria, including targetable biomarkers from DNA and RNA.
Leverage our end to end solutions to design and execute Tempus-sponsored clinical trials for therapeutics, devices, and diagnostics from study concept to registrational filing.
Timely AI-enabled notifications to accelerate adoption of precision care pathways and avoid gaps in care.
90%
of the top 20 pharma oncology companies partner with Tempus
200+
biopharma partnerships
~6M
de-identified research records to power scientific discovery to improve patient outcomes
800K+
records with matched clinical data linked with genomic information
~200K
records with whole transcriptome profiles
9
NGS tests to support clinical trial and research sequencing
6.5K+
oncologists rely on Tempus as their precision medicine partner
~10
business days for just-in-time trial activation
90+
health systems representing 500+ sites
26K+
patients have been identified for potential enrollment into clinical trials in our network
The Oncology Institute of Hope and Innovation (TOI) highlights how the Tempus TIME program amplified the ability to identify the right patient for the right study at the right time, while reducing the time and resources needed to open new clinical trials.
Read moreIn this panel session we spoke to Translational Scientists who have been utilizing multi-modal insights in their daily work and discussed what new information can come to light by utilizing these tools.
Watch replayDiscover how TriHealth leveraged TIME to dramatically increase clinical trial enrollment across their oncology portfolio, achieve increased ROI, and improve the overall quality of studies.
Read moreListen to industry leaders discuss longitudinal endpoints for disease progression, the evolving role of liquid biopsy within drug development, and the value of methylation in combination with liquid biopsy.
Watch replayLearn the value of RNA Sequencing in identifying altered expression programs in tumors that are measurable by RNA-Seq but not DNA-Seq.
Read moreGenetic testing has been a breakthrough in clinical research and patient profiling, allowing providers to pinpoint the precise factors in a person’s genome that may affect their health or response to treatments.
Read moreAI-Enabled Precision Medicine is Here: Leveraging insights derived from data to advance cancer care
Watch nowTempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel.
Watch replayLearn more about Gilead Sciences’ efforts to drive biomarker innovations and assemble their organization for integrated, data-driven research.
Read moreTempus, a leader in artificial intelligence and precision medicine, today announced the addition of a novel MRD assay, xM MRD (formerly xM), to its comprehensive testing solutions.
READ PRESS RELEASETempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with Recursion (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery.
READ PRESS RELEASETempus, a leader in artificial intelligence and precision medicine, today announced the integration of its signature Tempus One technology into its Lens data analytics platform.
READ PRESS RELEASEGet customized solutions for your needs.